The debate mentioned tau PTM targeting but did not identify which modifications are both disease-specific and accessible for therapeutic intervention. This knowledge gap limits the development of PTM-based selective targeting approaches.
Source: Debate session sess_SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd (Analysis: SDA-2026-04-08-gap-debate-20260406-062052-81a54bfd)
A quantitative threshold of phosphorylation (S396/S404), acetylation (K280), and truncation (D421) defines a pathological tau PTM signature that predicts therapeutic vulnerability better than any single modification alone.
No AI visual card yet
Dimension Scores
How to read this chart:
Each hypothesis is scored across 10 dimensions that determine scientific merit and therapeutic potential.
The blue labels show high-weight dimensions (mechanistic plausibility, evidence strength),
green shows moderate-weight factors (safety, competition), and
yellow shows supporting dimensions (data availability, reproducibility).
Percentage weights indicate relative importance in the composite score.
6 citations6 with PMID5 mediumValidation: 42%5 supporting / 1 opposing
✓For(5)
5
No opposing evidence
(1)Against✗
HighMediumLow
HighMediumLow
Evidence Matrix — sortable by strength/year, click Abstract to expand
Evidence Types
3
2
1
MECH 3CLIN 2GENE 1EPID 0
Claim
Stance
Category
Source
Strength ↕
Year ↕
Quality ↕
PMIDs
Abstract
Interactions between Microtubule-Associated Protei…
Multi-persona evaluation:
This hypothesis was debated by AI agents with complementary expertise.
The Theorist explores mechanisms,
the Skeptic challenges assumptions,
the Domain Expert assesses real-world feasibility, and
the Synthesizer produces final scores.
Expand each card to see their arguments.
Gap Analysis | 4 rounds | 2026-04-12 | View Analysis
🧬TheoristProposes novel mechanisms and generates creative hypotheses▼
Mechanistically-Specific Hypotheses: Disease-Specific and Therapeutically-Accessible Tau PTMs
Title: K280 acetylation defines pathogenic tau conformers
Mechanism: p300/CBP-mediated acetylation at K280 (within the microtubule-binding repeat domain) converts tau into a aggregation-competent state by disrupting microtubule binding while simultaneously creating a β-sheet nucleation interface. This acetylated form recruits unmodified tau into oligomers, functioning as a dominant-
🔍SkepticIdentifies weaknesses, alternative explanations, and methodological concerns▼
Skeptic's Evaluation of Mechanistically-Specific Tau PTM Hypotheses
Hypothesis 1: K280 Acetylation as Aggregation Nucleation Site
Strongest Specific Weakness
Mechanistic claim exceeds structural evidence. The assertion that K280 acetylation creates a "β-sheet nucleation interface" implies a defined conformational change, yet no atomic-resolution structure of acetylated tau exists showing how this modification templated aggregation. The proposed mechanism conflates correlation (K280 acetylation correlates with disease) with causation (acetylation drives nucleation). W
🎯Domain ExpertAssesses practical feasibility, druggability, and clinical translation▼
Domain Expert Assessment: Tau PTM Translational Potential
1. Prioritized Hypotheses by Translational Potential
Hypothesis A (Highest Priority): Truncation at Asp-421 as a Disease-Specific, Amplifiable Seed
Why this rises to top translational candidate:
| Dimension | Assessment | |-----------|------------| | Disease Specificity | C-terminal truncation at D421 is detected in human AD brain but not age-matched controls with normal cognition (Zhao et al., 2016; PMID: 26797856). Unlike phosphorylation (ubiquitous in aging), this cleavage event appears restricted to patho
⚖SynthesizerIntegrates perspectives and produces final ranked assessments▼
{ "ranked_hypotheses": [ { "rank": 1, "title": "Caspase-2/3-mediated D421 truncation generates disease-specific aggregation seeds", "mechanism": "Proteolytic cleavage at Asp-421 by caspase-2/3 produces aggregation-competent tau C-terminal fragments that are detected in human AD brain but absent in age-matched cognitively normal controls.", "target_gene": "CASP2/CASP3", "confidence_score": 0.75, "novelty_score": 0.55, "feasibility_score": 0.65, "impact_score": 0.85, "composite_score": 0.73, "testable_prediction": "Caspase-2 kno
Structured peer reviews assess evidence quality, novelty, feasibility, and impact. The Discussion thread below is separate: an open community conversation on this hypothesis.
IF human iPSC-derived cortical neurons are exposed to pathological seeds AND a combinatorial PTM threshold is met (phospho-S396/S404 ≥ 70% of total tau, acetyl-K280 ≥ 40%, and truncation at D421 ≥ 30% detected by targeted MS), THEN these neurons will exhibit ≥3-fold higher tau aggregation efficiency compared to neurons where only 1-2 of these PTMs exceed the threshold, within 14 days post-seeding.
pendingconf: 0.68
Expected outcome: Combinatorial signature (+) cells show significantly higher tau seeding/aggregation readouts (e.g., FRET-based aggregation assay, Sarkosyl-insoluble tau fraction) than partial-signature or single-modification cells.
Falsified by: Neurons with single PTM elevation (e.g., phospho-S396/S404 only, without acetylation or truncation) show equivalent aggregation efficiency to the combinatorial signature group, eliminating the added value of combinatorial assessment.
Method: iPSC-derived cortical neurons from ≥3 unrelated donors, transfected with full-length 2N4R MAPT, exposed to pathological tau seeds (Braak stage III-V brain homogenate), harvested at day 14 for targeted immuno-MRM MS quantification of PTMs and tau aggregation assays.
IF preclinical cohorts of P301S transgenic mice are stratified by the combinatorial tau PTM signature (threshold as defined above) versus single-modification stratification prior to anti-tau antibody treatment (e.g., AJ196), THEN the combinatorial-stratified group will show ≥40% improvement in therapeutic response (reduced insoluble tau by ELISA, normalized motor performance) compared to the single-modification-stratified group, within 8 weeks of treatment.
pendingconf: 0.55
Expected outcome: Mice meeting the full combinatorial signature show superior therapeutic response to anti-tau intervention, as measured by 50% reduction in Sarkosyl-insoluble tau and improved rotarod performance.
Falsified by: Mice stratified by a single PTM marker (e.g., phospho-S396/S404 alone) show equivalent or superior therapeutic response to the combinatorial stratification group, indicating the combinatorial approach does not improve predictive value over single markers.
Method: P301S mice (n≥20/group, mixed sex)perfused at 3 months of age, stratified using lumbar CSF sampling for PTM quantification by immunoassay, randomized to anti-tau antibody vs. isotype control, outcomes assessed by biochemical and behavioral readouts at 8 weeks post-treatment.